Practical Guide to Implementing AIR & SMART Webinar

AIR and SMART Therapy have been shown to reduce asthma related hospitalizations and exacerbations. This 60-minute webinar will address key information on the effectiveness of these new therapies and what you need to know to implement them in your practice. Join our moderator Angela Duff Hogan, MD and experts Drs. Leonard Bacharier, Alan Baptist, and Desiree Larenas-Linnemann for this informative presentation and discussion. Register now.

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Allergists, allied health and other allergy practitioners.

Learning Objectives

After completing this webinar, participants should be able to:
1. Describe the evidence for effectiveness of AIR & SMART therapies.
2. Apply AIR & SMART therapy to appropriate populations, selection of correct candidates.
3. Describe and utilize strategies to overcome barriers.
4. Identify the past and current ways of classifying asthma.
5. Apply guideline changes in asthma diagnosis, monitoring, and treatment based on evidence and shared decision making. 
6. Determine the strengths and limitations of the NIH Asthma Management Guidelines.


Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
  • 1.00 CBRN
Course opens: 
Course expires: 

Leonard B. Bacharier, MD
Leonard Bacharier, MD, is the Janie Robinson and John Moore Lee Chair in Pediatrics at Vanderbilt University Medical Center. He is a Professor of Pediatrics and Allergy/Immunology/Pulmonary Medicine. He is also the Scientific Director of the Center for Clinical and Translational Research at Vanderbilt. Dr. Bacharier's career has focused on clinical research to help understand and improve the care of children with asthma. His clinical/translational research efforts are directed at the pathogenesis of asthma in early life and approaches to asthma management throughout childhood, including multi-center federally funded clinical trials in asthma.

Alan P Baptist, MD, MPH
Alan P Baptist, MD, MPH, is a Professor and Division Head of Allergy and Clinical Immunology at Henry Ford Health in Detroit, Michigan and holds a joint appointment at University of Michigan School of Public Health in Ann Arbor, Michigan. He previously served on the NHLBI 2020 Asthma Guidelines Update Committee. His research interests include asthma in older adults, asthma healthcare disparities, and implementation of asthma guidelines. Dr Baptist has authored or coauthored over 80 peer-reviewed articles that have been published in journals such as the Journal of Allergy and Clinical Immunology and the Annals of Allergy, Asthma, and Immunology.

Angela Duff Hogan, MD, FAAAAI, FACAAI, FAAP
Angela Duff Hogan, MD, is Chair of the ACAAI Asthma Committee. She is a member of Children’s Allergy, Asthma, and Immunology, Children’s Specialty Group at Children’s Hospital of the King’s Daughters, and a professor of pediatrics at Eastern Virginia Medical School.

Desiree Larenas-Linnemann, MD
Desiree Larenas-Linnemann, MD is an allergist, clinical immunologist, and pediatrician. She is the Director of the Center of Excellence in Asthma and Allergy at Hospital Médica Sur, Mexico City. Mexico. With an H-index of 66, Dr. Larenas-Linnemann is an internationally known expert in (severe) asthma, allergen immunotherapy, allergic rhinitis, urticaria and atopic dermatitis and has chaired 10 National Mexican Guidelines on these disorders. She is national advocate to GINA since 2020, ARIA national coordinator since 2012, and a national coordinator for International Severe Asthma registry since 2019. She is a member of the National System of Researchers.

All identified relevant financial relationships with ineligible companies have been mitigated.

Leonard Bacharier, MD | Presenter | AstraZeneca, DBV Technologies, GlaxoSmithKline, Novartis, Sanofi
Alan P. Baptist, MD | Presenter | AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi
Angela Duff Hogan, MD | Moderator | GlaxoSmithKline, Novartis, Sanofi
Desiree Larenas-Linnemann, MD | Presenter | AbbVie, ALK-Abello, AstraZeneca, Bayer, Chiesi,  Grunenthal, Grin, GSK, Lilly, Menarini, Novartis, Pfizer, Pulmonair-Circassia, Sanofi, Siegfried

Angela Chan, MD | Planner
Meera Gupta, MD | Planner
Priya Jayesh Patel, MD | Planner
Joel Klein, MD | Planner 
Ellen Daily Stephen, MD | Planner
Charles Stewart, NP | Planner

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
  • 1.00 CBRN
Please login or create an account to take this course.